<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03298282</url>
  </required_header>
  <id_info>
    <org_study_id>1-2017-0049</org_study_id>
    <nct_id>NCT03298282</nct_id>
  </id_info>
  <brief_title>Integrated Coronary Multicenter Imaging Registry</brief_title>
  <official_title>Integrated Coronary Multicenter Imaging Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The coronary images of selective angiography and optical coherence tomography with&#xD;
      FFR(Fractional Flow Reserve) values of the intermediate lesions (40-70% stenosis) will be&#xD;
      prospectively registered.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients with intermediate lesions after CT angiography and invasive coronary angiography&#xD;
      will be screened, and optical coherence tomography, FFR and selective CT angiography will be&#xD;
      performed. The coronary images and FFR values will be registered, and the patients will be&#xD;
      followed-up up to 2 years to investigate the adverse clinical events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of plaque on coronary CTA for during 2 years</measure>
    <time_frame>at registration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of plaque on coronary CTA for during 2 years</measure>
    <time_frame>at 2-year follow up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of plaque on coronary OCT for during 2 years</measure>
    <time_frame>at registration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of plaque on coronary OCT for during 2 years</measure>
    <time_frame>at 2-year follow up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of FFR value during 2 years</measure>
    <time_frame>at registration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of FFR value during 2 years</measure>
    <time_frame>at 2-year follow up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of computational FFR derived from OCT to invasive FFR</measure>
    <time_frame>at registration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of computational FFR derived from OCT to invasive FFR</measure>
    <time_frame>at 2-year follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event for 2 years (myocardial infarction, cardiovascular death)</measure>
    <time_frame>within 2 years after registration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Power of plaque characteristics on coronary CTA for predicting adverse events</measure>
    <time_frame>within 2 years after registration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Power of plaque characteristics on OCT for predicting adverse events</measure>
    <time_frame>within 2 years after registration</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Imaging Registry</arm_group_label>
    <description>Imaging cohort: Patients with intermediate lesions</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OCT (Optical Coherence Tomography)</intervention_name>
    <description>Coronary images by OCT and selective CTA and FFR values will be registered.</description>
    <arm_group_label>Imaging Registry</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Coronary CTA</intervention_name>
    <description>Coronary images by OCT and Coronary CTA and FFR values will be registered.</description>
    <arm_group_label>Imaging Registry</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FFR</intervention_name>
    <description>Coronary images by OCT and selective CTA and FFR values will be registered.</description>
    <arm_group_label>Imaging Registry</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Tertiary cardiovascular hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who underwent coronary CT angiography because of chest pain&#xD;
&#xD;
          -  Patients who need OCT or FFR evaluation because of intermediate lesions according to&#xD;
             invasive angiography (diameter stenosis of 40-70%)&#xD;
&#xD;
          -  Age: 20-80 yrs&#xD;
&#xD;
          -  Patients who consent and fully understand the protocol&#xD;
&#xD;
          -  Patients who consent the clinical follow-up&#xD;
&#xD;
          -  Patients who can be followed-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who had contrast allergy&#xD;
&#xD;
          -  Patients who had unstable blood pressure needing the vasopressors&#xD;
&#xD;
          -  Patients who had severe left ventricular function (left ventricular ejection&#xD;
             fraction&lt;30%)&#xD;
&#xD;
          -  Chronic kidney disease who had Cr level of greater than 2.0 mg/dl&#xD;
&#xD;
          -  Patients whose expected survival is less than 12 months&#xD;
&#xD;
          -  Patients who had a severe valvular disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung-Sun Kim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Cardiology, Cardiovascular Hospital, Yonsei University</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 26, 2017</study_first_submitted>
  <study_first_submitted_qc>September 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2017</study_first_posted>
  <last_update_submitted>October 11, 2020</last_update_submitted>
  <last_update_submitted_qc>October 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

